Compare Indoco Remedies with Finolex Industries - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs FINOLEX INDUSTRIES - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

FINOLEX INDUSTRIES 
   Change

Established in 1981, Finolex Industries is the only integrated pipe manufacturer in India. It derives 72% of its earnings from the PVC business and the rest from pipes and fittings. The main demand for PVC comes from agricultural, housing, constructi... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES FINOLEX INDUSTRIES INDOCO REMEDIES/
FINOLEX INDUSTRIES
 
P/E (TTM) x 72.9 22.2 327.6% View Chart
P/BV x 4.2 2.8 151.6% View Chart
Dividend Yield % 0.3 1.7 18.7%  

Financials

 INDOCO REMEDIES   FINOLEX INDUSTRIES
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
FINOLEX INDUSTRIES
Mar-19
INDOCO REMEDIES/
FINOLEX INDUSTRIES
5-Yr Chart
Click to enlarge
High Rs317713 44.5%   
Low Rs178440 40.5%   
Sales per share (Unadj.) Rs113.1249.1 45.4%  
Earnings per share (Unadj.) Rs4.529.6 15.1%  
Cash flow per share (Unadj.) Rs11.835.2 33.5%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.41.7 23.3%  
Book value per share (Unadj.) Rs73.2207.6 35.3%  
Shares outstanding (eoy) m92.15124.10 74.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.3 94.7%   
Avg P/E ratio x55.519.5 284.7%  
P/CF ratio (eoy) x21.016.4 128.2%  
Price / Book Value ratio x3.42.8 121.8%  
Dividend payout %22.433.8 66.3%   
Avg Mkt Cap Rs m22,83071,537 31.9%   
No. of employees `0005.51.3 412.3%   
Total wages/salary Rs m2,2091,344 164.3%   
Avg. sales/employee Rs Th1,910.123,366.0 8.2%   
Avg. wages/employee Rs Th405.01,016.1 39.9%   
Avg. net profit/employee Rs Th75.52,775.9 2.7%   
INCOME DATA
Net Sales Rs m10,41930,913 33.7%  
Other income Rs m47404 11.6%   
Total revenues Rs m10,46631,317 33.4%   
Gross profit Rs m1,3495,764 23.4%  
Depreciation Rs m677701 96.6%   
Interest Rs m235123 191.6%   
Profit before tax Rs m4845,345 9.1%   
Minority Interest Rs m0140 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m721,812 4.0%   
Profit after tax Rs m4123,673 11.2%  
Gross profit margin %12.918.6 69.5%  
Effective tax rate %15.033.9 44.1%   
Net profit margin %4.011.9 33.3%  
BALANCE SHEET DATA
Current assets Rs m5,37310,535 51.0%   
Current liabilities Rs m4,1575,155 80.6%   
Net working cap to sales %11.717.4 67.1%  
Current ratio x1.32.0 63.2%  
Inventory Days Days6873 92.5%  
Debtors Days Days739 829.8%  
Net fixed assets Rs m6,24411,075 56.4%   
Share capital Rs m1841,241 14.9%   
"Free" reserves Rs m6,56624,521 26.8%   
Net worth Rs m6,75025,762 26.2%   
Long term debt Rs m1,2330-   
Total assets Rs m12,36333,327 37.1%  
Interest coverage x3.144.6 6.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.9 90.9%   
Return on assets %5.211.4 45.9%  
Return on equity %6.114.3 42.8%  
Return on capital %9.021.8 41.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,14312,301 9.3%   
Net fx Rs m2,619-12,301 -21.3%   
CASH FLOW
From Operations Rs m1,2274,074 30.1%  
From Investments Rs m-1,360-2,356 57.7%  
From Financial Activity Rs m-388-1,710 22.7%  
Net Cashflow Rs m-5218 -6,850.0%  

Share Holding

Indian Promoters % 59.2 52.5 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 4.6 271.7%  
FIIs % 6.0 4.8 125.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 38.2 58.6%  
Shareholders   12,805 130,070 9.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   MOTILAL OSWAL  TIL  BAJAJ FINANCE  INGERSOLL RAND  CCL INTERNATIONAL  



Today's Market

5 Reasons Why Sensex Plunged 536 Points Today(Closing)

Extending losses to the fifth straight session, Indian share markets witnessed selling pressure throughout the day today and ended deep in the red.

Related Views on News

FINOLEX INDUSTRIES Announces Quarterly Results (2QFY21); Net Profit Up 16.6% (Quarterly Result Update)

Oct 28, 2020 | Updated on Oct 28, 2020

For the quarter ended September 2020, FINOLEX INDUSTRIES has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 6 bn (up 1.6% YoY). Read on for a complete analysis of FINOLEX INDUSTRIES's quarterly results.

FINOLEX INDUSTRIES Announces Quarterly Results (1QFY21); Net Profit Down 24.0% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, FINOLEX INDUSTRIES has posted a net profit of Rs 551 m (down 24.0% YoY). Sales on the other hand came in at Rs 6 bn (down 40.4% YoY). Read on for a complete analysis of FINOLEX INDUSTRIES's quarterly results.

FINOLEX INDUSTRIES Announces Quarterly Results (3QFY20); Net Profit Up 18.6% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, FINOLEX INDUSTRIES has posted a net profit of Rs 933 m (up 18.6% YoY). Sales on the other hand came in at Rs 7 bn (down 7.6% YoY). Read on for a complete analysis of FINOLEX INDUSTRIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 28, 2021 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS